SCHEMBL339003

SCHEMBL339003

O=[C][C@@H]1C2C=CC(C2)[C@@H]1[C]=O

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5080176 1.00 ALDH1A1 (0.32) ALDH1A1TDP1
SCHEMBL13409249 0.69
SCHEMBL13409251 0.69
SCHEMBL5349953 0.69
SCHEMBL5372826 0.69
SCHEMBL2834144 0.63 ALDH1A1 (0.33) ALDH1A1
SCHEMBL7770261 0.62
SCHEMBL9616050 0.62
SCHEMBL9580055 0.62
SCHEMBL3453600 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119181-A1 Hydrophobically-modified protein compositions and methods BIOGEN IDEC INC. (US) 2005-06-02 US claimed
EP-1036092-B1 Hydrophobically-modified hedgehog protein compositions and methods BIOGEN INC (US) 2005-05-11 EP claimed
EP-1036092-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 2000-09-20 EP claimed
WO-1999028343-A9 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN INC (US) 1999-10-14 WO claimed
WO-1999028343-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 1999-06-10 WO claimed
EP-1646395-B1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY CURIS INC (US) 2014-11-05 EP disclosed
US-20120269863-A1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY CURIS, INC. (US) 2012-10-25 US disclosed
US-20120238500-A1 REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO CURIS, INC. (US) 2012-09-20 US disclosed
US-8168178-B2 Methods and compositions for regulating lymphocyte activity CURIS, INC. (US) 2012-05-01 US disclosed
US-8097253-B2 Methods for inhibiting angiogenesis UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-01-17 US disclosed
EP-2359842-A1 Netrin-related compositions and uses University of Utah Research Foundation (US) 2011-08-24 EP disclosed
US-20110124580-A1 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-05-26 US disclosed
WO-2000027422-A2 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PERIPHERAL NEUROPATHIES BIOGEN, INC. (US) 2000-05-18 WO disclosed
WO-2000015246-A2 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-03-23 WO disclosed
WO-1999028343-A9 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN INC (US) 1999-10-14 WO disclosed
WO-1999028343-A2 HYDROPHOBICALLY-MODIFIED PROTEIN COMPOSITIONS AND METHODS BIOGEN, INC. (US) 1999-06-10 WO disclosed
WO-1999020298-A1 REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO ONTOGENY, INC. (US) 1999-04-29 WO disclosed
WO-1999010004-A2 REGULATION OF MUSCLE TISSUES BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO ONTOGENY, INC. (US) 1999-03-04 WO disclosed
US-5801274-A N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1998-09-01 US disclosed
US-5591891-A PEPTIDASE INHIBITORS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1997-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238500-A1 REGULATION OF EPITHELIAL TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO SHH, SMO, GLI1 ALDH1A1 3638/4885TDP1 4619/4885
US-20110124580-A1 REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO SHH, FGF1, HGF ALDH1A1 2489/4885TDP1 4473/4885
US-20120269863-A1 METHODS AND COMPOSITIONS FOR REGULATING LYMPHOCYTE ACTIVITY SHH, ICOS, SMO ALDH1A1 4111/4885TDP1 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.